Olaparib, PARP1 inhibitor in ovarian cancer

Claudia Marchetti, Ludovica Imperiale, Maria Luisa Gasparri, Innocenza Palaia, Sandro Pignata, Terenzio Boni, Filippo Bellati, Pierluigi Benedetti Panici

Research output: Contribution to journalArticle


Introduction: Ovarian cancer is the most important cause of gynecological cancer-related mortality. Conventional treatments for advanced or recurrent disease offer limited results in terms of long-term responses and survival. Researches have recently focused on target therapies, which represent a new, promising, therapeutic approach, able to maximizing tumor kill and minimizing toxicity. The family of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors is currently one of the most hopeful and investigated alternatives. Areas covered: Preclinical and clinical studies of Olaparib, the most investigated PARP inhibitor in ovarian cancer, are analyzed and discussed. Data were obtained by searching for all English peer-reviewed articles on Medline, on Cochrane Database and all on-going Phase I and II studies registered on National Cancer Institute Clinical Trials; also any related abstracts recently presented on Olaparib at major international congresses will be included. Expert opinion: Bad prognosis and drug resistance usually affect ovarian cancer. Recent trends toward the knowledge of molecular-specific pathways have produced new target drugs. PARP inhibition mediated by Olaparib in BRCA1 (breast cancer 1) and BRCA2 (breast cancer 2)-mutated and in sporadic ovarian cancer represents a promising field of investigation. Further studies are needed to confirm initial exciting results.

Original languageEnglish
Pages (from-to)1575-1584
Number of pages10
JournalExpert Opinion on Investigational Drugs
Issue number10
Publication statusPublished - Oct 2012


  • BRCA1/2
  • Ovarian cancer
  • Polyadenosine diphosphate-ribose polymerase inhibitors
  • Target therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Olaparib, PARP1 inhibitor in ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Marchetti, C., Imperiale, L., Gasparri, M. L., Palaia, I., Pignata, S., Boni, T., Bellati, F., & Benedetti Panici, P. (2012). Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opinion on Investigational Drugs, 21(10), 1575-1584. https://doi.org/10.1517/13543784.2012.707189